JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML

Area of Science:

• Epigenetics and Cancer Biology
• Hematopoiesis and Leukemia Research

Background:

• JMJD3 is a stress-inducible histone demethylase involved in malignant hematopoiesis.
• Its precise role in different cell types and leukemia subtypes remains largely unknown.

Purpose of the Study:

• To investigate the cell type-dependent function of JMJD3 in acute myeloid leukemia (AML).
• To elucidate the molecular mechanisms underlying JMJD3's role in AML pathogenesis.

Main Methods:

• RNA sequencing to analyze gene expression changes.
• Chromatin immunoprecipitation followed by PCR (ChIP-PCR) to assess histone methylation.
• Co-immunoprecipitation to study protein interactions.

Main Results:

• JMJD3 exhibits an anti-leukemic effect in specific AML subtypes (M2 and M3) by promoting differentiation.
• JMJD3 directly modulates H3K4 and H3K27 methylation to activate key myelopoietic regulatory genes.
• A physical and functional association between JMJD3 and C/EBPβ was identified.

Conclusions:

• JMJD3's role in leukemia is context-dependent, acting as an oncoprotein in some malignancies and an oncorepressor in specific AML subsets.
• JMJD3's anti-AML activity is mediated through its interaction with C/EBPβ and regulation of myelopoietic genes.